Detalhe da pesquisa
1.
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3.
Ann Oncol
; 2024 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38729566
2.
Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2.
Ann Oncol
; 34(12): 1131-1140, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38072513
3.
Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial.
Ann Oncol
; 34(12): 1141-1151, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38072514
4.
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
Ann Oncol
; 32(12): 1571-1581, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34656740
5.
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.
Ann Oncol
; 30(6): 927-933, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30903140
6.
Corrigendum to "Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria": [Annals of Oncology 32 (2021) 950-953].
Ann Oncol
; 33(3): 356, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35012799
7.
Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance).
Ann Oncol
; 27(2): 339-44, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26578722
8.
Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria.
Ann Oncol
; 32(8): 950-953, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33991601
9.
Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm.
Ann Oncol
; 28(3): 673-675, 2017 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27993808
10.
CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.
Clin Pharmacol Ther
; 95(2): 216-27, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24060820
11.
CYP2D6 genotype and tamoxifen: considerations for proper nonprospective studies.
Clin Pharmacol Ther
; 96(2): 141-4, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25056392
12.
Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.
Clin Pharmacol Ther
; 83(1): 160-6, 2008 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-17882159
13.
The Hsp90 chaperone complex as a novel target for cancer therapy.
Ann Oncol
; 14(8): 1169-76, 2003 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-12881371